Unimas, Taiwan's CMUH host inaugural symposium on cutting-edge medical tech, patient care
KUCHING (July 12): Universiti Malaysia Sarawak (Unimas) and Taiwan's China Medical University Hospital (CMUH) co-hosted the inaugural symposium on 'Advances in Medical Technology and Patient Care' today, following a memorandum of understanding signed between the two institutions in 2024.
Unimas vice-chancellor Prof Dr Ahmad Hata Rasit, in a speech delivered on his behalf by Dean of the Faculty of Medicine and Health Sciences (FMHS) Prof Dr Asri Said, said the university actively fosters global partnerships to boost research impact and enrich student learning.
'This symposium marks the beginning of what I believe will be a vibrant and enduring academic relationship between CMUH and Unimas,' he said.
CMUH International Center Superintendent Dr Chih-Kun Huang said the event not only showcased Taiwan's progress in precision medicine and healthcare innovation but also marked a new chapter of collaboration with Malaysia.
'We look forward to deepening our shared mission of improving health outcomes across borders,' he added.
The symposium featured frontier advancements in medical technology and clinical care, with a strong focus on obesity management, cancer treatment, medical artificial intelligence, Parkinson's disease interventions, and atrial fibrillation therapies.
During his session, Huang outlined a multidisciplinary approach to obesity treatment that goes beyond conventional methods such as lifestyle modification and pharmacotherapy.
He highlighted emerging innovations including novel anti-obesity agents, personalised interventions based on genetics and the microbiome, and less invasive endoscopic bariatric therapies, advancements especially relevant for countries like Malaysia where obesity rates are on the rise.
Director of Radiation Oncology at CMUH Dr Chun-Ru Chien, presented the clinical advantages of proton therapy over conventional radiotherapy, noting its ability to precisely target tumours while sparing surrounding healthy tissue, thus reducing side effects.
President of the World Federation of Neuroradiological Societies Dr Wan-Yuo Guo, highlighted how medical artificial intelligence (AI) is transforming healthcare by integrating complex data such as imaging, genomics, pathology, and clinical records.
He emphasised AI's role in enhancing diagnostic accuracy and enabling predictive, preventive, and personalised medicine.
Asri (second left) presents a memento to Huang during the opening of the symposium in Kuching.
In the field of neurology, Director of Neurology at CMUH Dr Jui-Cheng Chen, introduced the world's first dual-target Magnetic Resonance-guided Focused Ultrasound (MRgFUS) procedure for Parkinson's disease, a non-invasive treatment that helps relieve symptoms such as tremor and rigidity, particularly for patients unsuited for deep brain stimulation.
Also featured was senior consultant in Otorhinolaryngology-Head and Neck Surgery at FMHS Unimas Prof Dr Ing Ping Tang, who reviewed recent advancements in otology implants, including cochlear, bone conduction, middle ear, and auditory brainstem implants.
He underscored their growing role in managing complex hearing conditions for patients who gain minimal benefit from conventional hearing aids.
From the Faculty of Resource Science and Technology at Unimas, Prof Dr Edmund Sim introduced the Cancer Risk Assessment Toolkit (CARISA), a subscription-based multilingual digital platform for early cancer risk screening.
It integrates five disease-specific modules covering breast, nasopharyngeal, cervical, lung, and colorectal cancers, and supports English, Malay, Mandarin, and Iban.
Rounding off the event, Director of the Cardiac Arrhythmia Center at CMUH Dr Yen-Nien Lin shared CMUH's integrated approach to atrial fibrillation management, reducing stroke risk and the need for long-term anticoagulation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
4 days ago
- New Straits Times
Evolutionary origins of the potato revealed - and a tomato was involved
THE potato is one of the world's food staples, first cultivated thousands of years ago in the Andes region of South America before spreading globally from the 16th century. But despite its importance to humankind, the evolutionary origins of the potato have remained puzzling - until now. A new analysis of 450 genomes from cultivated potatoes and 56 genomes of wild potato species has revealed that the potato lineage originated through natural interbreeding between a wild tomato plant and a potato-like species in South America about 9 million years ago. This hybridisation event led to the appearance of the nascent potato plant's tuber, an enlarged structure housing nutrients underground, according to the researchers, who also identified two crucial genes involved in tuber formation. Whereas in a tomato plant the edible part is the fruit, in the potato plant it is the tuber. "Potatoes are truly one of humanity's most remarkable food staples, combining extraordinary versatility, nutritional value and cultural ubiquity in ways few crops can match," said Sanwen Huang, a genome biologist and plant breeder at the Chinese Academy of Agricultural Sciences and senior author of the study published on Friday in the journal Cell. "People eat potatoes using virtually every cooking method - baking, roasting, boiling, steaming and frying. Despite being stereotyped as carbohydrates, potatoes offer vitamin C, potassium, fiber and resistant starch, and are naturally gluten-free, low-fat and satiating - a nutrient-dense calorie source," Huang added. Resistant starch is a type of carbohydrate that resists digestion in the small intestine and ferments in the large intestine, feeding beneficial bacteria in the gut. The modern-day potato plant's scientific name is Solanum tuberosum. Its two parents identified in the study were plants that were the ancestors of a potato-like species now found in Peru named Etuberosum, which closely resembles the potato plant but lacks a tuber, and the tomato plant. These two plants themselves shared a common ancestor that lived about 14 million years ago, and were able to naturally interbreed when the fortuitous hybridisation event occurred five million years after they had diverged from each other. "This event led to a reshuffling of genes such that the new lineage produced tubers, allowing these plants to expand into the newly created cold, dry habitats in the rising Andes mountain chain," said botanist Sandra Knapp of the Natural History Museum in London, a co-author of the study. This hybridisation event coincided with the rapid uplift of the Andes. With a tuber, the potato plant was able to adapt to the changing regional environment and thrive in the harsh conditions of the mountains. "Tubers can store nutrients for cold adaptation, and enable asexual reproduction to meet the challenge of the reduced fertility in cold conditions. These allowed the plant to survive and rapidly expand," Huang said. The study's findings, according to the researchers, may help guide improved cultivated potato breeding to address environmental challenges that crops presently face due to factors such as climate change. There currently are roughly 5,000 potato varieties. The potato is the world's third most important food crop, after rice and wheat, for human consumption, according to the Peru-based International Potato Centre research organisation. China is the world's leading potato producer. "It always is hard to remove all the deleterious mutations in potato genomes in breeding, and this study opens a new door to make a potato free of deleterious mutations using the tomato as the chassis of synthetic biology," Huang said. The study also may open the door to generate a new crop species that could produce tomato fruit above ground and potato tubers below ground, according to Zhiyang Zhang, a postdoctoral researcher at the Chinese Academy of Agricultural Sciences. The potato and tomato are members of the nightshade family of flowering plants that also includes tobacco and peppers, among others. The study did not investigate the evolutionary origins of other tuberous root crops that originated in South America such as the sweet potato and yuca, which are members of different families of flowering plants. While the parts of the tomato and potato plants that people eat are quite different, the plants themselves are very similar. "We use different parts of these two species, fruits in tomatoes and tubers in potatoes," Knapp said. "If you look at the flowers or leaves, these are very similar. And if you are lucky enough to let your potato plant produce fruits, they look just like little green tomatoes. But don't eat them. They are not very nice."
Malay Mail
4 days ago
- Malay Mail
Perak Sultan's son among dozens stung by jellyfish during open water meet in Teluk Senangin
KUALA LUMPUR, Aug 3 — At least 30 swimmers, including Raja Kecil Besar Raja Azlan Muzzaffar Shah, were stung by jellyfish during the Teluk Senangin Open Water Swim 2025 held early Saturday morning, according to the New Straits Times. The incident occurred at around 9am, prompting immediate medical attention for several participants. Raja Azlan, the son of the Sultan of Perak, Sultan Nazrin Muizzuddin Shah, and Raja Permaisuri Perak Tuanku Zara Salim, was among those affected but reportedly remained in good condition and completed his swim. A Perak Civil Defence Force (APM) spokesperson told the New Straits Times that 'about 30 to 40 swimmers were stung, likely by jellyfish, shortly after the event began.' 'Initial treatment was administered at the on-site medical base by APM and medical personnel from both private and government agencies,' the spokesman said, adding that two children — a nine-year-old from Kajang and a 10-year-old from Lekir — were taken to Seri Manjung Hospital for further treatment. The event, organised by AMMJB Swimmers Enterprise, drew hundreds of swimmers and spectators. Event director Saiful Nizam Kamal Arifin confirmed to the New Straits Times that Raja Azlan, who participated in the 3km swim for the 12–19 age group, was stung on the leg but was unfazed. 'He got stung on the leg, but it was very minor. I think, if you really look closely, it's just red, like something bit him, like a mosquito bite. But he's okay,' Saiful said. 'At that time, Tuanku (Zara) asked him during the first loop, 'Are you okay?' and he said, 'Yeah, okay, okay, I'm going for another loop.' He was fine. And he even finished it in style.' Saiful noted that jellyfish are one of the many natural challenges faced in open water swimming, alongside weather conditions and ocean currents.
Malaysian Reserve
28-07-2025
- Malaysian Reserve
Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies
No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic alpha-synuclein while preserving normal function is vital for early intervention and better outcomes. Late-stage candidates like Buntanetap (Annovis Biopharm), Prasinezumab (Roche/Prothena), and Amlenetug (Lundbeck) highlight growing innovation and competition in the alpha-synuclein inhibitors market. LAS VEGAS, July 28, 2025 /PRNewswire/ — DelveInsight's Alpha-synuclein Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Parkinson's disease, Alzheimer's disease, Lewy body dementia, Multiple system atrophy, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging alpha-synuclein inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the Alpha-synuclein Inhibitors Market Report As per DelveInsight's analysis, the total market size of alpha-synuclein inhibitors in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as Parkinson's disease, Alzheimer's disease, Lewy body dementia, Multiple system atrophy, and others. Leading alpha-synuclein inhibitors companies, such as Annovis Biopharm, Lundbeck, Roche, Prothena, and others, are developing novel alpha-synuclein inhibitors that can be available in the alpha-synuclein inhibitors market in the coming years. Some of the key alpha-synuclein inhibitors in the pipeline include Buntanetap, Amlenetug, Prasinezumab, and others. In March 2025, Annovis Bio participated in AD/PD 2025, scheduled from April 1–5 in Vienna. During the conference, the company Annovis gave two presentations, showcasing findings from its Phase III Parkinson's disease trial and data on buntanetap in ApoE4 carriers from its Phase II/III Alzheimer's disease study. In February 2025, the FDA granted Fast Track Designation (FTD) to amlenetug for the treatment of MSA. In January 2025, Annovis Bio secured a significant milestone with the issuance of a US patent protecting its novel methods for treating and preventing acute brain and nerve injuries through buntanetap. Discover which indication is expected to grab the major alpha-synuclein inhibitors market share @ Alpha-synuclein Inhibitors Market Report Alpha-synuclein Inhibitors Market Dynamics The alpha-synuclein inhibitors market is driven by the growing prevalence of neurodegenerative disorders such as Parkinson's disease, Lewy body dementia, and multiple system atrophy, where alpha-synuclein aggregation plays a critical pathogenic role. With the global burden of Parkinson's disease expected to double by 2040, there is a pressing demand for disease-modifying therapies that can go beyond symptomatic relief. Current treatment options, such as dopaminergic drugs, primarily address motor symptoms but fail to halt disease progression. This unmet medical need is pushing pharmaceutical and biotechnology companies to focus on alpha-synuclein inhibitors, which target the underlying pathology by preventing protein misfolding, aggregation, and the subsequent neurodegenerative cascade. Significant research and development investments are shaping the competitive landscape of the alpha-synuclein inhibitors market. Several leading pharmaceutical players are actively pursuing monoclonal antibodies and small molecule inhibitors targeting alpha-synuclein. Clinical trials have advanced the understanding of the therapeutic potential of targeting alpha-synuclein, though some setbacks have been observed due to limited clinical efficacy in late-stage trials. Nonetheless, advancements in biomarker discovery and imaging technologies for early diagnosis and monitoring disease progression are expected to enhance the success rate of ongoing and future clinical programs. Market dynamics are also influenced by regulatory and reimbursement factors. Given the high cost and complexity of neurodegenerative disease drug development, regulatory agencies like the FDA and EMA are encouraging accelerated pathways and breakthrough therapy designations for promising candidates. However, high development costs, combined with stringent clinical efficacy requirements, pose challenges for new entrants and smaller biotech firms. Moreover, reimbursement policies in major markets will play a critical role in determining the commercial success of these therapies once approved. Collaborations and strategic partnerships are increasingly shaping the alpha-synuclein inhibitors landscape. Big pharmaceutical companies are entering licensing agreements, mergers, or co-development partnerships with biotech firms to expand their neurodegenerative pipelines. For instance, Roche and Prothena's collaboration on prasinezumab reflects the industry trend of leveraging external innovation to accelerate drug development. Furthermore, increasing venture capital funding and public-private initiatives are supporting the growth of innovative startups working on novel alpha-synuclein-targeting approaches, such as antisense oligonucleotides and gene therapy-based strategies. Looking ahead, the alpha-synuclein inhibitors market is poised for steady growth. The next decade is expected to witness significant milestones in the approval and commercialization of disease-modifying therapies, which could revolutionize the treatment paradigm for Parkinson's and related disorders. Alpha-synuclein Inhibitors Treatment Market Alpha-synuclein inhibitors are therapeutic agents developed to prevent the aggregation of alpha-synuclein, a protein closely linked to neurodegenerative disorders such as Parkinson's disease, Lewy body dementia, and multiple system atrophy. These inhibitors function by blocking protein misfolding, reducing toxic buildup, and promoting clearance pathways. By targeting alpha-synuclein pathology, they aim to slow the progression of these diseases, offering promising advancements in neuroprotection and symptom relief. Although no alpha-synuclein inhibitors have yet received regulatory approval, the FDA has issued a 'Letter of Support' encouraging the use of the synuclein-based biomarker, αSyn-SAA, in clinical trials for Parkinson's disease and related disorders. This recognition underscores the biomarker's potential to improve disease monitoring, streamline drug development, and refine treatment strategies. With no approved therapies in this category, several companies, including Annovis Bio, Roche/Prothena, and Lundbeck, are actively progressing their pipelines to develop innovative candidates. These initiatives aim to enhance therapeutic approaches, improve drug effectiveness, and address the significant unmet needs in neurodegenerative conditions such as Parkinson's, Lewy body dementia, and MSA. Learn more about the alpha-synuclein inhibitors @ Alpha-synuclein Inhibitors Analysis Key Emerging Alpha-synuclein Inhibitors and Companies Emerging alpha-synuclein inhibitors in the pipeline, including buntanetap (Annovis Biopharm), prasinezumab (Roche/Prothena), amlenetug (Lundbeck), and others, are showing promise for expanding treatment options. Buntanetap, formerly known as Posiphen or ANVS401, works against neurodegeneration by preventing the build-up of toxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43. This action helps boost synaptic function, improve axonal transport, and reduce neuroinflammation—key processes required to maintain healthy neurons. The accumulation of these proteins disrupts neural pathways, leading to neuronal damage and cell death, which underlie diseases like Alzheimer's and Parkinson's. By targeting these mechanisms, buntanetap aims to reverse neurodegeneration, restore brain function, and significantly enhance patients' quality of life. In March 2025, Annovis Bio participated in the AD/PD 2025 conference (April 1–5, Vienna), where it delivered two presentations highlighting data from its Phase III Parkinson's disease trial and findings on buntanetap in ApoE4 carriers from its Phase II/III Alzheimer's disease study. Earlier, in July 2024, Annovis announced results from its Phase III Parkinson's disease trial (NCT05357989). Among patients diagnosed with Parkinson's for over three years, buntanetap demonstrated significant improvements in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores, Parts II, III, II+III, and Total, compared with placebo and baseline. Prasinezumab, an experimental monoclonal antibody, is designed to selectively bind aggregated alpha-synuclein (α-syn) and reduce its neurotoxic effects. By targeting α-syn accumulation and its cell-to-cell spread, prasinezumab has the potential to slow disease progression. Targeting α-syn aggregates is supported by extensive research as a viable therapeutic strategy for Parkinson's disease. At the AD/PD 2025 conference, the company presented results from the Phase IIb PADOVA study. While the drug showed potential in slowing motor symptom progression, it did not achieve statistical significance in the primary analysis, and further evaluations are ongoing. Amlenetug, a human monoclonal antibody, is designed to bind all major extracellular forms of α-syn, preventing their uptake and halting aggregation seeding. Its active Fc region may promote immune-mediated clearance of α-syn/antibody complexes through microglial uptake, thereby reducing pathological deposits. Developed by Lundbeck in collaboration with Genmab A/S, amlenetug is part of ongoing efforts to develop disease-modifying therapies for neurodegenerative conditions. In February 2025, the FDA granted Fast Track Designation (FTD) for amlenetug in treating multiple system atrophy (MSA). It previously received Orphan Drug Designation (ODD) from the FDA in April 2024, SAKIGAKE designation from Japan's Ministry of Health, Labour and Welfare in March 2023, and ODD from the European Medicines Agency (EMA) in May 2021. The anticipated launch of these emerging therapies are poised to transform the alpha-synuclein inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the alpha-synuclein inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about alpha-synuclein inhibitors clinical trials, visit @ Alpha-synuclein Inhibitors Treatment Alpha-synuclein Inhibitors Overview Alpha-synuclein is a highly soluble and intrinsically disordered protein that accumulates in Lewy bodies and Lewy neurites, playing a key role in the development of Parkinson's disease and other synucleinopathies. While predominantly located in the brain, smaller amounts are also present in the heart, muscles, and various tissues. Within neurons, α-Syn is concentrated in presynaptic terminals, where it regulates synaptic vesicle dynamics. Studies indicate that it may restrict vesicle mobility, thereby influencing synaptic recycling and neurotransmitter release. Another view suggests that α-Syn interacts with VAMP2 (synaptobrevin) to stabilize SNARE complexes, with recent research linking these interactions to synaptic function. Moreover, α-Syn may modulate dopamine release, affecting both voluntary and involuntary motor control. Synucleinopathies are marked by the accumulation of α-Syn amyloid deposits in the brain, driving neurodegeneration. Preventing α-Syn aggregation remains challenging due to its inherently disordered structure and the complex, unpredictable nature of fibrillogenesis. Nevertheless, targeting α-Syn is considered a promising therapeutic strategy, offering potential avenues for the treatment of Parkinson's disease and related conditions. Alpha-synuclein Inhibitors Epidemiology Segmentation The alpha-synuclein inhibitors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases in Selected Indications for Alpha-synuclein Inhibitors Total Eligible Patient Pool in Selected Indications for Alpha-synuclein Inhibitors Total Treated Cases in Selected Indications for Alpha-synuclein Inhibitors Alpha-synuclein Inhibitors Report Metrics Details Study Period 2020–2034 Alpha-synuclein Inhibitors Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report Parkinson's disease, Alzheimer's disease, Lewy body dementia, Multiple system atrophy, and others Key Alpha-synuclein Inhibitors Companies Annovis Biopharm, Lundbeck, Roche, Prothena, and others Key Alpha-synuclein Inhibitors Buntanetap, Amlenetug, Prasinezumab, and others Scope of the Alpha-synuclein Inhibitors Market Report Alpha-synuclein Inhibitors Therapeutic Assessment: Alpha-synuclein Inhibitors current marketed and emerging therapies Alpha-synuclein Inhibitors Market Dynamics: Conjoint Analysis of Emerging Alpha-synuclein Inhibitors Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Alpha-synuclein Inhibitors Market Access and Reimbursement Discover more about alpha-synuclein inhibitors in development @ Alpha-synuclein Inhibitors Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary 4 Key Events 5 Market Forecast Methodology 6 Alpha-synuclein Inhibitors Market Overview at a Glance in the 7MM 6.1 Market Share (%) Distribution by Indication in 2024 6.2 Market Share (%) Distribution by Indication in 2034 7 Alpha-synuclein Inhibitors: Background and Overview 7.1 Introduction 7.2 Evolution of Alpha-synuclein Inhibitors 7.3 Treatment 8 Target Patient Pool 8.1 Key Findings 8.2 Assumptions and Rationale: 7MM 8.3 Epidemiology Scenario in the 7MM 8.3.1 Total Cases in Selected Indications for Alpha-synuclein Inhibitors in the 7MM 8.3.2 Total Eligible Patient Pool in Selected Indications for Alpha-synuclein Inhibitors in the 7MM 8.3.3 Total Treated Cases in Selected Indications for Alpha-synuclein Inhibitors in the 7MM 8.4 The US 8.4.1 Total Cases in Selected Indications for Alpha-synuclein Inhibitors in the US 8.4.2 Total Eligible Patient Pool in Selected Indications for Alpha-synuclein Inhibitors in the US 8.4.3 Total Treated Cases in Selected Indications for Alpha-synuclein Inhibitors in the US 8.5 EU4 and the UK 8.5.1 Total Cases in Selected Indications for Alpha-synuclein Inhibitors in EU4 and the UK 8.5.2 Total Eligible Patient Pool in Selected Indications for Alpha-synuclein Inhibitors in EU4 and the UK 8.5.3 Total Treated Cases in Selected Indications for Alpha-synuclein Inhibitors in EU4 and the UK 8.6 Japan 8.6.1 Total Cases in Selected Indications for Alpha-synuclein Inhibitors in Japan 8.6.2 Total Eligible Patient Pool in Selected Indications for Alpha-synuclein Inhibitors in Japan 8.6.3 Total Treated Cases in Selected Indications for Alpha-synuclein Inhibitors in Japan 9 Emerging Therapies 9.1 Key Cross Competition 9.2 Buntanetap: Annovis Biopharma 9.2.1 Drug Description 9.2.2 Others Developmental Activities 9.2.3 Clinical Trials Information 9.2.4 Safety and Efficacy 9.2.5 Analyst's View 9.3 Prasinezuma: Roche/Prothena 9.4 Amlenetug: Lundbeck List of drugs to be continued in the final report… 10 Alpha-synuclein Inhibitors: the 7MM Analysis 10.1 Key Findings 10.2 Key Market Forecast Assumptions 10.2.1 Cost Assumptions and Rebates 10.2.2 Pricing Trends 10.2.3 Analogue Assessment 10.2.4 Launch Year and Therapy Uptakes 10.3 Market Outlook 10.4 Attribute Analysis 10.5 Total Market Size of Alpha-synuclein Inhibitors in the 7MM 10.6 The US Market Size 10.6.1 Total Market Size of Alpha-synuclein Inhibitors in the US 10.6.2 Market Size of Alpha-synuclein Inhibitors by Therapies in the US 10.7 EU4 and the UK Market Size 10.7.1 Total Market Size of Alpha-synuclein Inhibitors in EU4 and the UK 10.7.2 Market Size of Alpha-synuclein Inhibitors by Therapies in EU4 and the UK 10.8 Japan Market Size 10.8.1 Total Market Size of Alpha-synuclein Inhibitors in Japan 10.8.2 Market Size of Alpha-synuclein Inhibitors by Therapies in Japan 11 Unmet Needs 12 SWOT Analysis 13 KOL Views 14 Market Access and Reimbursement 14.1 The US 14.2 EU4 and the UK 14.3 Japan 15 Bibliography 16 Report Methodology Related Reports Parkinson's Disease Market Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, LLC, among others. Alzheimer's Disease Market Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies including AB Science, Alzheon Inc., AriBio Co., Ltd., AgeneBio, Inc., Anavex Life Sciences Corp., Annovis Bio, Inc., Cerecin, BioVie, Cassava Sciences, Novo Nordisk, Eli Lilly, Neurim Pharmaceuticals, Suven Life Sciences, Bristol-Myers Squibb, Karuna Therapeutics, T3D Therapeutics, Inc., Lexeo Therapeutics, Axsome Therapeutics, Inc., Araclon Biotech S.L., Eisai Co., Ltd., TauRx Therapeutics, TrueBinding, Inc., AC Immune SA, Johnson & Johnson, Longeveron Inc., Vaccinex Inc., IGC Pharma LLC, among others. Multiple System Atrophy Market Multiple System Atrophy Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MSA companies including H Lundbeck A/S, Brain Neurotherapy Bio, Inc., Asklepios BioPharmaceutical, Inc., Theravance Biopharma, Ono Pharmaceutical Co. Ltd, Ionis Pharmaceuticals, Inc., Biogen, Alterity Therapeutics, Teva Pharmaceutical, MODAG GmbH, among others. Lewy Body Dementia Market Lewy Body Dementia Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Lewy body dementia companies including EIP Pharma Inc., Cognition Therapeutics, Eisai Inc., Sun Pharma Advanced Research Company Limited, Georgetown University, Eli Lilly and Company, CuraSen Therapeutics, Inc., Athira Pharma, Aptinyx Inc., among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content:
